Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc.

Pfizer CentreOne

Anacor Pharmaceuticals

Pfizer Medical

Bamboo Therapeutics, Inc. a wholly owned subsidiary of Pfizer Inc.

Breakthroughs That Change Patients' Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.To learn more, visit www.pfizer.com.  

For additional information on our guidelines, please visit  http://www.pfizer.com/community-guidelines

Beware of scams from individuals, organizations and Internet sites claiming to represent Pfizer in recruitment activities. A formal Pfizer recruitment process is required for all authorized positions posted by Pfizer prior to issuing an offer of employment. This Pfizer process includes an interview and never requires payment or fees from job applicants. If you receive a suspicious email message or phone call about recruiting on behalf of Pfizer, do not provide any personal information or pay any fees. Interested candidates should apply to current openings through this Pfizer website. Pfizer accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

Cortexyme

ESSA Pharma

Zentalis Pharmaceuticals

Caribou Biosciences

Allogene Therapeutics

Spero Therapeutics

Sema4

Amplyx Pharmaceuticals

Imara

Cerevel Therapeutics

LianBio

Merus

Valneva

NextCure

NovoCure

ORIC Pharmaceuticals

Protalix BioTherapeutics

Pfizer

As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. 
 
One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). 

We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. 

In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change.

#CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.

Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.

https://lnkd.in/e2kgTGNp

Wishing Ultromics success with their development of EchoGo® Amyloidosis. This exciting tech uses AI to analyze routine ultrasound scans of the heart, known as an echocardiogram or echo. Our hope is that AI will offer an early warning to help physicians suspect and detect cardiac amyloidosis earlier🤞. Find out more below.

We are excited to announce that the U.S. FDA granted approval to our combination therapy from Seagen for locally advanced/metastatic urothelial cancer, developed with Astellas Pharma US and Merck. We look forward to the potential of this therapy to become a new standard of care for these patients. Read more here: https://lnkd.in/ev4uTdYe

Pfizer is proud to provide an unrestricted donation to the American Association for Cancer Research (AACR), the first and largest cancer research organization formed in the world. This donation will directly support AACR in its mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research. 
 
Thank you to the AACR for your partnership in accelerating the discovery of new breakthroughs in order to bring new hope to people living with cancer around the world.

Learn about tangible solutions to disrupt structural inequities in healthcare facilities and delivery in our final ‘Health Equity in Action’ Health Affairs Forefront series post, co-authored by Walter D. Conwell, MD, MBA, Chief Diversity and Inclusion Officer at Morehouse School of Medicine, and Niesha Foster, our VP of Global Health and Social Impact: https://bit.ly/3T5ZrH9

In this piece, they share practical insights and underscore the need to:
✔️ promote patient-centric care
✔️ address the social determinants of health as part of care plans
✔️ invest in the training and wellness of healthcare providers, among other priorities.

#EquityInAction #PublicHealth #HealthEquity #Partnership

Finding innovative ways to make clinical trials accessible and accelerating breakthroughs to patients is how we continue to push science forward. We are proud to introduce the first industry-sponsored research registry called PfizerLink.

PfizerLink aims to make it easier for interested individuals to find Pfizer clinical trials, including for those who have been historically underrepresented, and address the long-standing challenges associated with clinical trial recruitment. This novel online approach will allow people who are interested – either healthy volunteers or those with medical conditions – to be rapidly pre-screened and connected to a trial navigator that will connect them to an available Pfizer clinical trial nearby or notify them if one becomes available.

The registry helps address the frustrations some people feel in searching for and learning about new trials. In fact, the most recent CISCRP study on the public’s attitudes towards clinical research found that despite higher levels of awareness, a quarter of respondents are not confident in their ability to find a clinical research study that is right for them.

Industrywide, approximately 80% of clinical trials fail to meet enrollment deadlines, while 30% of Phase 3 studies last longer than expected due to challenges in recruitment. Because potentially eligible participants would already be identified and pre-screened through PfizerLink, enrollment in newly launched Pfizer trials can be significantly accelerated. 

PfizerLink aims to make it easier for potential participants to get involved in the research that matters to them.

To learn more about PfizerLink, please visit https://www.pfi.sr/SkM.

Below are some highlights from our Q3 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/eKE6B9qW

BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). 

This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. 
 
Learn more about this breakthrough at https://lnkd.in/eNSit2TD

BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).

Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.

Read more: https://lnkd.in/efgEVrK7

NYSE:PFE

Pfizer

Last Close

27.85

09/05 20:00

Market Cap

155.11B

Beta: 0.59

Volume Today

172.79K

Avg: 21.42M

PE Ratio

14.35

PFCF: 18.40

Dividend Yield

6.19%

Payout:87.54%

Financials Not Available